Literature DB >> 1337550

Polymerase chain reaction assay for hepatitis C virus RNA using a single tube for reverse transcription and serial rounds of amplification with nested primer pairs.

H J Lin1, N Shi, M Mizokami, F B Hollinger.   

Abstract

A procedure is described for the detection of hepatitis C virus (HCV) RNA in blood by means of the polymerase chain reaction (PCR) in which the reverse transcription step and two rounds of amplification are carried out in a single tube. This results in fewer manipulations, reduced risk of contamination, and economy of time. The procedures are generally applicable to other assays based on the PCR. We describe the preparation (from 100 microL serum) of test samples that remain stable for at least 6 days under specified conditions and an assay that employs nested primer pairs homologous to conserved sequences in the 5' noncoding region. The method was tested on 107 sera from the United States and Japan. Correlation with first-generation anti-HCV was 77%. Two sets of nested primer pairs homologous to sequences in the 5' noncoding region and one set based on structural region sequences showed differences in their reactivities with serum HCV RNA. The recommended single tube procedure specified a primer for reverse transcription that was conserved in all reported HCV genomes but absent from pestivirus genomic sequences. The effects of preanalytical factors on the detection of HCV RNA were studied. Qualitatively, there was no change in the HCV RNA-positivity of sera that were exposed to room temperature for 24 hours. Quantitative studies showed a decrease in titer in some specimens. Three cycles of freeze-thawing had no detectable effects on the titers of HCV RNA.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1337550     DOI: 10.1002/jmv.1890380312

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  8 in total

1.  Multitypic hepatitis C virus infection identified by real-time nucleotide sequencing of minority genotypes.

Authors:  Andrew J Buckton; Siew-Lin Ngui; Catherine Arnold; Katie Boast; Joanne Kovacs; Paul E Klapper; Bharat Patel; Imad Ibrahim; Savita Rangarajan; Mary E Ramsay; Chong-Gee Teo
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

2.  Ribonucleotide vanadyl complexes inhibit polymerase chain reaction.

Authors:  J Y Lau; K P Qian; P C Wu; G L Davis
Journal:  Nucleic Acids Res       Date:  1993-06-11       Impact factor: 16.971

3.  Effect of multiple freeze-thaw cycles on hepatitis B virus DNA and hepatitis C virus RNA quantification as measured with branched-DNA technology.

Authors:  M Krajden; J M Minor; O Rifkin; L Comanor
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

4.  Prevalence and significance of hepatitis GB virus-c/hepatitis G virus viremia in a large cohort of patients with chronic hepatitis B infection, with chronic hepatitis C infection, and on renal replacement therapy in Hong Kong.

Authors:  Man-Fung Yuen; Tak-Mao Chan; Terence Pok-Siu Yip; John Chi-Hang Yuen; Stephen Ka-Nung Ho; Ching-Lung Lai
Journal:  Dig Dis Sci       Date:  2002-02       Impact factor: 3.199

Review 5.  Hepatitis C: progress and problems.

Authors:  J A Cuthbert
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

6.  Rapid and sensitive method for detection of hepatitis C virus RNA by using silica particles.

Authors:  R C Cheung; S M Matsui; H B Greenberg
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

7.  Early detection of anti-HCc antibody in acute hepatitis C virus (HCV) by western blot (immunoblot) using a recombinant HCV core protein fragment.

Authors:  C T Yeh; C M Han; S Y Lo; J H Ou; K D Fan; I S Sheen; C M Chu; Y F Liaw
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

8.  Diversity of hepatitis C virus quasispecies evaluated by denaturing gradient gel electrophoresis.

Authors:  K A Harris; C G Teo
Journal:  Clin Diagn Lab Immunol       Date:  2001-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.